Rhythm Pharmaceuticals (RYTM)

• Market cap: $6.84B
• 1 day: -1.14%
• 5 days: 0.33%
• 1 month: -3.97%
• 3 months: -8.31%
• 6 months: 21.1%
• Year to date: -2.37%
• 1 year: 73.12%
• 5 years: 235.47%
• 10 years: 241.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Employees: 283